Transient enterohepatic circulation and enhanced biliary versus urinary excretion of the cytostatic drug bischolylglycinate-chloroplatinum(II) (Bamet-H2)

International Journal of Pharmaceutics

Volumn 172, Issue 1-2, 1998, Pages 79-88

  Palomero, Maria F ^a   Herrera, Maria C ^a   MacIas, Rocio I R ^a   El Mir, Mohamed Y ^a   Villanueva, Gloria R ^a   Marin, Jose J G ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Bile Acid; Cancer; Chemotherapy; Glycocholate; Kidney; Liver; Metal; Pharmacokinetics; Tumor

Indexed keywords

BISCHOLYLGLYCINATE CHLOROPLATINUM (II); CISPLATIN; CISPLATIN DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

EID: 0032531822     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00178-1     Document Type: Article

References (35)

1. Almé B., Bremmelgaard A., Sjovall J., Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatography-mass spectrometry. J Lipid Res. 18:1977;339-362.
2. Azer S.A., Stacey N.H. Current concepts of hepatic uptake intracellular transport and biliary secretion of bile acids: physiological basis and pathophysiological changes in cholestatic liver dysfunction. J. Gastroenterol. Hepatol. 11:1996;396-407.
3. Betebenner D.A., Carney P.L., Zimmer A.M., Kazikiewicz J.M. Hepatobiliary delivery of polyaminopolycarboxylate chelates: synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate. Bioconjugate Chem. 2:1991;117-123.
4. Binks S.P., Dobrota M. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. Biochem. Pharmacol. 40:1990;1329-1336.
5. Buscher H.P., Gerok W., Kollinger M., Kurz G., Muller M., Nolte A., Schneider S. Transport systems for amphipathic compounds in normal and neoplastic hepatocytes. Adv. Enzyme. Regul. 27:1988;173-192.
6. Campbell A.B., Kalman S.M., Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat. Rep. 67:1983;169-172.
7. Criado J.J., Herrera M.C., Palomero M.F., Medarde M., Rodriguez E., Marin J.J.G. Synthesis and characterization of a new bile acid and platinum(II) complex with cytostatic activity. J. Lipid Res. 38:1997;1022-1032.
8. Daugaard G., Abildgaard U., Holstein-Rathlou N.H., Bruunshuus I., Bucher D., Leyssac P.P. Renal tubular function in patients treated with high-dose cisplatin. Clin. Pharmacol. 44:1988;164-172.
9. Daugaard G., Rossing N., Rorth M. Effect of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother. Pharmacol. 21:1988;163-167.
10. DeConti R.C., Toftness B.R., Lange R.C., Creasey W.A. Clinical and pharmacological studies with cis-diammineplatinum(II). Cancer Res. 33:1973;1310-1315.
11. Desoize B., Berthiot G., Manot L., Coninx P., Dumont P. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur. J. Cancer. 32:1996;1734-1738.
12. Desoize B., Marechal F., Millart H., Cattan A. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed. Pharmacother. 45:1991;203-207.
13. Desoize B., Robert J. Individual dose adaptation of anticancer drugs. Eur. J. Cancer. 30:1994;844-851.
14. Goel R., Andrews P.A., Pfeifle C.E., Abramson I.S., Kirmani S., Howell S.B. Comparison of the pharmacokinetics of ultrafiltrable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur. J. Cancer. 26:1990;21-27.
15. Gonzalez-Vitale J.C., Hayes D.M., Cvitkovic E., Sternberg S.S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 39:1977;1362-1371.
16. Gromley P.E., Bull J.M., LeRoy A.F., Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin. Pharmacol. Ther. 25:1979;351-357.
17. Ho N.F.H. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann. N.Y. Acad. Sci. 907:1987;315-329.
18. Hofmann, A.F., 1994. Biliary secretion and excretion -The hepatobiliary component of the enterohepatic circulation of bile acids. In: Johnson L.R. (Ed.) Physiology of the gastrointestinal tract. Raven Press, New York, pp. 1555-1576.
19. Hylemon P.B. Metabolism of bile acids in intestinal microflora. New Compr. Biochem. 12:1985;331-343.
20. Kelsen D.P., Alcock N., Young C.W. Cisplatin nephrotoxicity. Correlation with plasma concentrations. Am. J. Clin. Oncol. 8:1985;77-80.
21. Kramer W., Wess G. Bile acid transport systems as pharmaceutical targets. Eur. J. Clin. Invest. 26:1996;715-732.
22. Kramer W., Wess G., Schubert G., Bickel M., Girbig F., Gutjart U., Kowalewski S, Barinhaus K.H., Enhsen A., Glombik H., Mullner S., Neckermann G., Schulz S., Petzinger E. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. 267:1992;18598-18604.
23. Kroker R., Anwer M.S., Hegner D. The lack of active bile acid transport in AS-30D ascites hepatoma cells. Naunyn Schmiedeberg's Arch. Pharmacol. 303:1978;299-301.
24. Kullak-Ublick G.A., Beuers U., Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 23(5):1996;1053-1060.
25. Kullak-Ublick G.A., Glasa J., Boker C., Oswald M., Grutzner U., Hagenbuch B., Stieger B., Meier P.J., Beuers U., Kramer W., Wess G., Paumgartner G. Chlorambucil taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology. 113:1997;1295-1305.
26. Loeher P.J., Einhorn L.H. Cisplatin. Ann. Int. Med. 100:1984;704-713.
27. Ma J., Verweij J., Kolker H.J., Vaningen H.E., Stoter G., Schellens J.H.M. Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an iv bolus and 3 h and 20 h infusion. Br. J. Cancer. 69(5):1994;858-862.
28. Marchegiano P., Carubbi F., Tiribelli C., Amarri S., Stebel M., Lunazzi G.C., Levy D., Bellentani S. Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochem. Biophys. Res. Commun. 183:1992;1203-1208.
29. Marin, J.J.G., Herrera, M.C., Palomero, M.F., Macias, R.I.R., Monte, M.J., El-Mir, M.Y., Villanueva, G.R., 1998. Rat liver transport and biotransformation of a cytostatic complex of bischolylglicinate and platinum(II). J. Hepatol. 28, 417-425.
30. Marin J.J.G., Herrera M.C., Palomero M.F., Macias R.I.R., Monte M.J., Villanueva G.R., El-Mir M.Y., Serrano M.A., Criado J.J. "In vivo" distribution, toxicity and cytostatic capacity of platinated bile acid analogs [abstract]. Hepatology. 24:1996;372A.
31. Miyazaki, M., Namba, M., 1994. Hepatocellular Carcinomas. In: Hay, R.J., Park, J.G., Gazdar, A. (Eds.) Atlas of human tumor cell lines. Academic Press, San Diego, pp. 185-221.
32. Stephan Z.F., Yurachek E.C., Sharif R., Wasvary J.M., Steele R.E., Howes C. Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem. Pharmacol. 43:1992;1969-1974.
33. Villanueva G.R., Mendoza M.E., El-Mir M.Y., Monte M.J., Herrera M.C., Marin J.J.G. Effect of bile acids on hepatobiliary transport of cisplatin by perfused rat liver. Pharmacol. Toxicol. 80:1997;111-117.
34. Von Dippe P., Levy D. Expression of the bile acid transport proteins during liver development and in hepatoma cells. J. Biol. Chem. 265:1990;5942-5945.
35. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:1978;547-557.